Duality Biotherapeutics, Inc. (“DualityBio”) disclosed a mix of share repurchases and option exercises that marginally adjusted its capital structure as of 28 May 2026.

DualityBio repurchased 47,800 ordinary shares on 28 May 2026 through on-market transactions, paying between HKD 208.40 and HKD 217.60 per share. The volume-weighted average repurchase price was approximately HKD 212.88, for a total consideration of HKD 10.18 million. The repurchased shares have been retained as treasury stock, lifting the treasury share balance from 30,000 to 77,800.

In parallel, employees (non-director) exercised options under the Pre-IPO Equity Incentive Plan (adopted 28 February 2021; amended 25 June 2023), resulting in the issuance of 21,000 new ordinary shares—12,600 shares on 27 May at an average HKD 215.92 per share and 8,400 shares on 28 May at HKD 216.49 per share.

After accounting for these movements, DualityBio’s issued share capital excluding treasury shares decreased by 26,800 shares, moving from 90.52 million to 90.50 million, a reduction of 0.03%. Total issued shares (including treasury) edged up to 90.58 million.

The latest buy-back utilised 47,800 of the 8.80 million shares authorised under the repurchase mandate granted on 20 June 2025, bringing cumulative purchases under the mandate to 77,800 shares, or 0.09% of the shares outstanding at the mandate date. Pursuant to Hong Kong Stock Exchange rules, DualityBio is subject to a moratorium on new share issues or treasury share disposals until 27 June 2026.